Novartis gives R&D update at the 2009 first half

Novartis AG reported net income of $4 billion at the 2009 first half and confirmed its forecast for a “strong operational performance” for the year as a whole. The company also said its cancer therapy, Afinitor, should be approved in the EU soon.